# Not well with Wellbutrin? Examining a case of bupropion-associated exacerbation of psychosis in an adolescent girl - URL: https://alisanburak.com/en/wcp-2026-posterler/ev1124 - Language: en - Last updated: not specified - Page title: Not well with Wellbutrin? Examining a case of bupropion-associated exacerbation of psychosis in an adolescent girl | WCP 2026 Summary > An adolescent patient with early-onset psychotic disorder who had been stable on treatment experienced a marked exacerbation of psychosis after bupropion was a… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/ev1124) This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it. EV1124 E-PosterPsychopharmacologyCase Report # Not well with Wellbutrin? Examining a case of bupropion-associated exacerbation of psychosis in an adolescent girl UNWELL ON WELLBUTRIN? EXPLORING A CASE OF RELAPSED PSYCHOSIS WITH BUPROPION IN AN ADOLESCENT GIRL Presenter: Jamie Odzer Country: United States of America Institution: University of Miami Miller School of Medicine / Jackson Health System An adolescent patient with early-onset psychotic disorder who had been stable on treatment experienced a marked exacerbation of psychosis after bupropion was added for depressive symptoms; improvement followed discontinuation of the drug and adjustment of antipsychotic treatment. The aim is to discuss, through a case report, how bupropion, generally considered safe despite its dopaminergic effects, may exacerbate psychosis in pediatric patients with psychotic disorders. The study design is a single case report. A 17-year-old girl with a history of depression and schizophrenia was admitted for inpatient treatment of acutely decompensated psychosis, presenting with disorganized thinking, paranoid and bizarre (Capgras) delusions, and auditory hallucinations; she had experienced psychotic symptoms since age 15 and had a history of early cannabis use, currently in remission. Although her symptoms had been well controlled with aripiprazole 10 mg and sertraline 200 mg, and medication adherence had been reported, her depressive symptoms worsened six months before admission, prompting the addition of bupropion XL to her regimen, titrated to 300 mg daily. Despite marked improvement in mood, increased anxiety, auditory hallucinations, and paranoia emerged at subsequent outpatient visits; her condition deteriorated, with disorganization, withdrawal, and Capgras delusions becoming severe enough to require hospitalization. Bupropion and aripiprazole were discontinued, and olanzapine was initiated and titrated to 20 mg. Initial improvement in psychotic symptoms was documented, and perceptual disturbances had resolved by discharge. Because paranoia persisted at monthly follow-up, she was switched to haloperidol for its higher dopamine D2 receptor affinity, with a good response. The authors emphasize the need for caution and close monitoring when prescribing high-dose bupropion to pediatric patients with preexisting psychotic disorders and a history of psychoactive substance use, noting that research in this area remains limited. [View the original poster](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1936) How to cite this study APA 7: Odzer, J., et al. (2026, September 23-26). Unwell on wellbutrin? exploring a case of relapsed psychosis with bupropion in an adolescent girl [E-poster]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1936 Vancouver: Odzer J, et al. Unwell on wellbutrin? exploring a case of relapsed psychosis with bupropion in an adolescent girl [e-poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1936 Author names and title formatting were generated automatically from the congress system; please check them against the original poster before use. ## On the same topic - [Açığı kapatmak: erişkin DEHB ilacı başlanmadan önce EKG sevk uyumunun iyileştirilmesi, kapalı döngü klinik denetim](https://alisanburak.com/en/wcp-2026-posterler/ev0088) - [Anksiyete bozukluğu olan hastalarda psikobiyotik müdahalesi: ısıl işlem görmüş Lactobacillus paracasei PS23'ün etkilerini inceleyen çift kör randomize kontrollü çalışma](https://alisanburak.com/en/wcp-2026-posterler/ev0126) - [Otizm spektrum bozukluğunda bumetanidin tedavi edici potansiyeli: güncel kanıtlar ve gelecek yönelimleri](https://alisanburak.com/en/wcp-2026-posterler/ev0157) - [Verbaskozid ile otizm spektrum bozukluğu tedavisinin mekanizmaları: ağ farmakolojisi, moleküler yerleştirme ve moleküler dinamik temelli inceleme](https://alisanburak.com/en/wcp-2026-posterler/ev0172) - [Otizm spektrum bozukluğunun çekirdek belirtilerinin tedavisinde kannabidiol: sistematik derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0186) [All WCP 2026 summaries](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/ev1124 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim